Editorial
Split Viewer
Blood Res 2014; 49(3):
Published online September 25, 2014
https://doi.org/10.5045/br.2014.49.3.139
© The Korean Society of Hematology
Way to go to exploit NK cells' versatile talents for cancer immunotherapy
Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Caligiuri, MA. Human natural killer cells. Blood, 2008;112;461-469.
- NK cell expansion. Kuerten, Germany: NKcells.info; [Accessed September 19, 2014]. , at http://www.nkcells.info/index.php?title=NK_cell_expansion
- Cho, D, Campana, D. Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med, 2009;29;89-96.
- Lim, SA, Kim, TJ, Lee, JE, et al. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. Cancer Res, 2013;73;2598-2607.
- Denman, CJ, Senyukov, VV, Somanchi, SS, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One, 2012;7;e30264.
- Bae, DS, Lee, JK. Development of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line. Blood Res, 2014;49;154-161.
- Kim, JK, Chung, JS, Shin, HJ, et al. Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood Res, 2014;49;162-169.
- Song, MK, Chung, JS, Seol, YM, et al. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann Oncol, 2010;21;140-144.
- Hurvitz, SA, Betting, DJ, Stern, HM, et al. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res, 2012;18;3478-3486.
- Bekaii-Saab, TS, Roda, JM, Guenterberg, KD, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther, 2009;8;2983-2991.
PDF
Standard view
Export citation
Share Article
Editorial
Blood Res 2014; 49(3): 139-140
Published online September 25, 2014 https://doi.org/10.5045/br.2014.49.3.139
Copyright © The Korean Society of Hematology.
Way to go to exploit NK cells' versatile talents for cancer immunotherapy
Duck Cho, M.D.
Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Caligiuri, MA. Human natural killer cells. Blood, 2008;112;461-469.
- NK cell expansion. Kuerten, Germany: NKcells.info; [Accessed September 19, 2014]. , at http://www.nkcells.info/index.php?title=NK_cell_expansion
- Cho, D, Campana, D. Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med, 2009;29;89-96.
- Lim, SA, Kim, TJ, Lee, JE, et al. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. Cancer Res, 2013;73;2598-2607.
- Denman, CJ, Senyukov, VV, Somanchi, SS, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One, 2012;7;e30264.
- Bae, DS, Lee, JK. Development of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line. Blood Res, 2014;49;154-161.
- Kim, JK, Chung, JS, Shin, HJ, et al. Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood Res, 2014;49;162-169.
- Song, MK, Chung, JS, Seol, YM, et al. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann Oncol, 2010;21;140-144.
- Hurvitz, SA, Betting, DJ, Stern, HM, et al. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res, 2012;18;3478-3486.
- Bekaii-Saab, TS, Roda, JM, Guenterberg, KD, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther, 2009;8;2983-2991.
Previous Article
